Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms
TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Thomas CLUZEAU
- Numero di telefono: +33 0492039025
- Email: cluzeau.t@chu-nice.fr
Backup dei contatti dello studio
- Nome: Caroline Fileni
- Email: fileni.c@chu-nice.fr
Luoghi di studio
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, Francia, 06000
- CHU de Nice
-
Contatto:
- Thomas CLUZEAU
- Numero di telefono: +33 0492039025
- Email: cluzeau.t@chu-nice.fr
-
Contatto:
- Caroline Fileni
- Email: fileni.c@chu-nice.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
TP53 mutated AML and HR-MDS patients
Descrizione
Inclusion Criteria:
- TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
- Age: Age ≥ 18 years
- Allo-HCT was permitted.
- Available NGS analysis at diagnosis
- TP53 VAF > 2%
- Myeloid sarcoma were permitted
- Patients received at least 1 treatment line
Exclusion Criteria:
- TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data
- TP53 CCUS or CHIP
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: RETROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
TP53 mutated myeloid neoplasms from Nice University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
|
TP53 mutated myeloid neoplasms from Saint-Louis University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Description of clinical outcomes according to treatment patterns
Lasso di tempo: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort |
Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
HCT as a time-dependent exposure.
Lasso di tempo: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
Description of transplanted patients to assess HCT as a time-dependent exposure. |
Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
|
Pre-HCT TP53 variant allelic frequency (VAF)
Lasso di tempo: Baseline
|
Variant allelic fraquency of TP53 at diagnosis |
Baseline
|
|
Molecular prognostic
Lasso di tempo: Baseline
|
To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF |
Baseline
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Amministrazione dei servizi sanitari
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Diagnosi
- Meccanismi di valutazione dell'assistenza sanitaria
- Qualità dell'assistenza sanitaria
- Valutazione dei risultati, assistenza sanitaria
- Esito e valutazione del processo, assistenza sanitaria
- Prognosi
- Esito del trattamento
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 26Hemato01
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .